Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care

What happened

Profound Medical and Telix Pharmaceuticals entered a formal co-education agreement intended to educate physicians and prostate cancer centers about the complementary roles of Telix’s PSMA-targeting PET imaging and Profound’s MRI-guided TULSA-PRO platform. The agreement establishes a framework for joint educational activity and seeks to raise awareness of PSMA-informed treatment pathways to support patient selection and treatment planning.

Sources: S1

Planned initiatives

The companies described a range of planned collaborative activities including participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, and the development of educational content, clinical case studies and best-practice materials. Profound said the collaboration is intended to increase physician awareness of PSMA-informed treatment pathways and expand access to the TULSA Procedure.

Sources: S1

Product and technical plans

Profound states it is developing PSMA-PET–MR image-fusion capabilities for a planned future release of its Treatment Delivery Console (TDC) software to allow Telix’s diagnostic PSMA-PET data to be incorporated into TULSA-PRO treatment planning. The company asserts that combining MRI and PSMA-PET imaging could enable more precise patient stratification and support tailored ablation strategies.

Sources: S1

Why this could matter (inference)

If the planned education and software functionality are adopted, clinicians may have additional diagnostic information when evaluating candidates for TULSA-PRO, which Profound characterizes as potentially aiding patient selection, treatment planning, determination of ablation extent, and margin definition. The firms frame the work as intended to enhance market development and clinician awareness rather than as completed clinical validation.

Sources: S1

Companies

Profound Medical is described as a commercial-stage medical device company that develops and markets the MRI-guided TULSA-PRO platform and Sonalleve. Telix Pharmaceuticals is described as a commercial-stage global radiopharmaceutical company with a precision diagnostics portfolio including Illuccix and Gozellix.

Sources: S1

What remains uncertain

• All operational and clinical benefits described are issuer statements from the press release and are not independently verified in the source.
• Planned software capabilities for PSMA-PET–MR image fusion are described as under development and part of a "planned future release"; timing, performance, and regulatory status are not specified in the source.
• Claims that PSMA-PET imaging could broaden the population considered for the TULSA Procedure are presented as a potential and are not accompanied by clinical trial results or quantified outcomes in the source.